Could a diabetes drug protect kidneys by fixing fat?
NCT ID NCT07309094
First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 17 times
Summary
This study looks at how a type of diabetes medicine (GLP-1 receptor agonists) affects fat tissue function in people with chronic kidney disease. Researchers want to see if improving fat health can slow kidney damage. About 250 adults with early-to-moderate kidney disease, obesity, or type 2 diabetes will take the drug and have their fat and kidney health measured over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vithas Valencia Consuelo
RECRUITINGValencia, Valencia, 46007, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.